Design Therapeutics Inc (NASDAQ: DSGN) stock jumped 0.45% on Monday to $2.23 against a previous-day closing price of $2.22. With 0.72 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.69 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.2680 whereas the lowest price it dropped to was $2.1800. The 52-week range on DSGN shows that it touched its highest point at $15.52 and its lowest point at $1.94 during that stretch. It currently has a 1-year price target of $4.75. Beta for the stock currently stands at 1.55.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DSGN was up-trending over the past week, with a rise of 8.78%, but this was up by 3.72% over a month. Three-month performance surged to 6.70% while six-month performance fell -70.35%. The stock lost -83.79% in the past year, while it has lost -78.27% so far this year. A look at the trailing 12-month EPS for DSGN yields -1.29 with Next year EPS estimates of -1.40. For the next quarter, that number is -0.31. This implies an EPS growth rate of -13.60% for this year and -7.92% for next year.
Float and Shares Shorts:
At present, 55.90 million DSGN shares are outstanding with a float of 32.56 million shares on hand for trading. On Oct 30, 2023, short shares totaled 3.12 million, which was 5.57% higher than short shares on Sep 28, 2023. In addition to Mr. Pratik Shah Ph.D. as the firm’s Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson, Dr. Sean Jeffries Ph.D. serves as its Chief Operating Officer.
Through their ownership of 70.11% of DSGN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.18% of DSGN, in contrast to 38.40% held by mutual funds. Shares owned by individuals account for 29.47%. As the largest shareholder in DSGN with 8.99% of the stake, Logos Global Management LP holds 5,032,501 shares worth 5,032,501. A second-largest stockholder of DSGN, RTW Investments LP, holds 2,512,986 shares, controlling over 4.49% of the firm’s shares. Citadel Advisors LLC is the third largest shareholder in DSGN, holding 2,261,199 shares or 4.04% stake. With a 1.36% stake in DSGN, the iShares Russell 2000 ETF is the largest stakeholder. A total of 763,248 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 0.73% of DSGN stock, is the second-largest Mutual Fund holder. It holds 411,201 shares valued at 0.84 million. Vanguard Extended Market Index Fu holds 0.71% of the stake in DSGN, owning 399,505 shares worth 0.81 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DSGN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DSGN analysts setting a high price target of $6.00 and a low target of $4.00, the average target price over the next 12 months is $4.75. Based on these targets, DSGN could surge 169.06% to reach the target high and rise by 79.37% to reach the target low. Reaching the average price target will result in a growth of 113.0% from current levels.
Summary of Insider Activity:
Insiders traded DSGN stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 2,268,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 13 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 4,090,450 while 0 shares were sold.